During their trials, they didn’t have a PD-L1 regulating drug such as Leronlimab. When PD-L1 gets unregulated and the tumor becones ‘hot’ exposed to the bodies own immune system, all ICI checkpoint inhibitors will benefit. Even the one you’re focused on.